Related references
Note: Only part of the references are listed.Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019
Robert J. Wong et al.
JAMA NETWORK OPEN (2020)
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Zobair Younossi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis
Jiaye Liu et al.
TRANSPLANT INFECTIOUS DISEASE (2019)
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
Nancy Reau et al.
HEPATOLOGY (2018)
Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients
Kosh Agarwal et al.
JOURNAL OF HEPATOLOGY (2018)
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition
Gonzalo Crespo et al.
JOURNAL OF HEPATOLOGY (2018)
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy
Ada Bertoli et al.
SCIENTIFIC REPORTS (2018)
Proposal of a simple scheme of direct action antivirals for HCV treatment in a public health system with low budget
Pedro Valdez-Hernandez et al.
SALUD PUBLICA DE MEXICO (2018)
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals
Stacey B. Prenner et al.
JOURNAL OF HEPATOLOGY (2017)
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
Fred Poordad et al.
HEPATOLOGY (2016)
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns et al.
LANCET INFECTIOUS DISEASES (2016)
Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients
Josh Levitsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir
P. Badri et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation
Vincent Leroy et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
An Interferon-free Antiviral Regimen for HCV after Liver Transplantation
Paul Y. Kwo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cholestatic hepatitis C following liver transplantation: An outcome-based histological definition, clinical predictors, and prognosis
Elizabeth C. Verna et al.
LIVER TRANSPLANTATION (2013)
Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
L Castéra et al.
GASTROENTEROLOGY (2005)
Share Paper
